Literature DB >> 31345734

The use of steroid cream for physiologic phimosis in male infants with a history of UTI and normal renal ultrasound is associated with decreased risk of recurrent UTI.

C J Chen1, A Satyanarayan1, B J Schlomer2.   

Abstract

BACKGROUND: An uncircumcised male infant with a history of urinary tract infection (UTI), physiologic phimosis, and a normal renal ultrasound is a common patient referred to pediatric urology clinics. Topical steroid creams have been shown to effectively release physiologic phimosis.
OBJECTIVE: The objective of this study was to test the hypothesis that use of steroid cream for physiologic phimosis is associated with a lower UTI recurrence in uncircumcised male infants with normal renal ultrasounds. STUDY
DESIGN: Uncircumcised males younger than 12 months referred for a UTI with a normal renal ultrasound were included. A longitudinal data set was created, and recurrent UTIs were identified. The proportion with a recurrent UTI was compared between those who received a prescription for a steroid cream for phimosis and those who did not. The morbidity of the initial and recurrent UTIs was also described. The association of recurrent UTI with vesicoureteral reflux (VUR) was also evaluated.
RESULTS: A total of 192 uncircumcised males with a median age of 5.8 months (interquartile range [IQR]: 3.5-7.9 months) were included. Twenty-seven patients were treated with a course of betamethasone valerate 0.1% cream, and 165 were not (Summary Table). There were no significant differences between groups in the frequency of voiding cystourethrogram (VCUG), diagnosis of VUR, or use of continuous prophylactic antibiotics (CAP). During a median follow-up of 8.7 months (IQR: 3.1-17.5 months), none of the patients treated with steroid cream had a recurrent UTI compared with 27 of 165 (16%) patients not treated (P = 0.02). Among the 173 patients whose initial UTI was febrile, recurrent febrile UTIs occurred in no treated patients and 23 of 150 (15%) untreated patients (P = 0.047). DISCUSSION: The results of this study are consistent with those of a previous randomized trial of steroid cream for physiologic phimosis which found lower recurrent UTI in those whose foreskins became retractable. In addition, the results are consistent with the declining incidence of UTIs in uncircumcised males mirroring the natural history of physiologic phimosis resolving. This study is limited by its retrospective nature and non-standardized follow-up.
CONCLUSION: The use of steroid cream for physiologic phimosis is associated with a decreased risk of recurrent UTIs in uncircumcised male infants with a normal renal ultrasound. In this group, steroid cream for physiologic phimosis is a well-tolerated and simple alternative to circumcision to potentially decrease risk of recurrent UTI.
Copyright © 2019 Journal of Pediatric Urology Company. Published by Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Neonatal urinary tract infection; Physiologic phimosis; Steroid cream; Urinary tract infection

Year:  2019        PMID: 31345734     DOI: 10.1016/j.jpurol.2019.06.018

Source DB:  PubMed          Journal:  J Pediatr Urol        ISSN: 1477-5131            Impact factor:   1.830


  2 in total

1.  Pathogen distribution and risk factors for urinary tract infection in infants and young children with retained double-J catheters.

Authors:  Jianfeng Wang; Yu Cao; Li Zhang; Guoqing Liu; Chunjing Li
Journal:  J Int Med Res       Date:  2021-05       Impact factor: 1.671

2.  Management of Pediatric Urinary Tract Infections: A Delphi Study.

Authors:  Giovanni Autore; Luca Bernardi; Claudio La Scola; Filippo Ghidini; Federico Marchetti; Andrea Pasini; Luca Pierantoni; Claudia Castellini; Claudia Gatti; Cristina Malaventura; Gabriella Pelusi; Francesco Antodaro; Andrea Bergomi; Franco Mazzini; Giovanni Parente; Roberto Pillon; Francesca Cusenza; Giacomo Biasucci; Alessandro De Fanti; Lorenzo Iughetti; Serafina Perrone; Andrea Pession; Mario Lima; Susanna Esposito
Journal:  Antibiotics (Basel)       Date:  2022-08-18
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.